

# ASX ANNOUNCEMENT

6 February 2023

## PROPOSED \$50 MILLION CAPITAL FACILITY

**BRISBANE, Australia and MINNEAPOLIS, USA:** Anteris Technologies Ltd (**Anteris** or the **Company**) (ASX: AVR) is pleased to announce that the Company has entered into a non-binding agreement with Yorkville Advisors Global, LP (**Investor**) to provide a \$50 million SEPA facility to Anteris.

Under the agreement it is proposed that Anteris can require the Investor to subscribe for new shares in Anteris by issuing a drawdown notice, up to a maximum of \$50 million worth of new shares over a 36 month period. Shares issued under the drawdown notice would be issued at a price equal to 93% of the lowest daily VWAP over a five-day period after Anteris gives the drawdown notice to the Investor. Each drawdown may be up to the greater of such amount as is equal to 200% of the average daily traded value during the 5 days immediately prior to the date the Company requests each drawdown, or A\$5,000,000. Each placement will utilize the Company's existing placement capacity under Listing Rule 7.1 or 7.1A as determined at the date of each placement or as otherwise advised to the market. A \$500,000 commitment fee would be payable to the Investor, \$250,000 of which may be settled in ordinary shares or cash (at Anteris' election).

The non-binding agreement is subject to the Investor's due diligence and internal approvals process, and entry into a binding agreement. The Company will announce to the Market any additional details including any security required at the time of finalizing the binding agreement. Anteris and the Investor are targeting entering into a binding agreement by the end of February 2023.

Mr. Wayne Paterson, Anteris' Chief Executive Officer, said: *"We are very pleased to partner with Yorkville Advisors. As a long only fund Yorkville has deployed over USD 5 bn to companies at various stages of their lifecycles around the world with structured solutions such as stand by equity purchase plans.*

*During 2023 Anteris will pass significant milestones on the path to commercialization. This new capital facility provides us with an ongoing source of capital and will become an integral part of our capital management strategy as we move ahead and significantly expand the patient population implanted with DurAVR™ including our US Early Feasibility Study in 2023".*

### **About Yorkville:**

*Yorkville Advisors Global, LP ("Yorkville") is a SEC-registered, global investment manager to a number of private investment funds. Since inception in 2001, Yorkville has been providing growth and acquisition capital to public companies across the globe. Yorkville invests through customized structured debt, equity investments and customized instruments, including the Standby Equity Purchase Agreement (SEPA). More information can be found on its website [www.yorkvilleadvisors.com](http://www.yorkvilleadvisors.com).*

**ENDS**

### **Anteris Technologies Ltd Registered Office:**

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

### **Customer Service**

T +61 1300 550 310 | F +61 1300 972 437 | E [info.au@anteristech.com](mailto:info.au@anteristech.com) | W [anteristech.com](http://anteristech.com)

Brisbane • Minneapolis • Geneva • Malaga



### **About Anteris Technologies Ltd (ASX: AVR)**

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

Its focus is developing next-generation technologies that help healthcare professionals deliver consistent life-changing outcomes for patients.

Anteris' DurAVR™ 3D single-piece aortic heart valve replacement addresses the needs of today's younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient's lifetime.

The proven benefits of its patented ADAPT® tissue technology, paired with the unique design of our DurAVR™ 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.

### **Authorisation and Additional information**

This announcement was authorised by Mr Wayne Paterson, Chief Executive Officer.

### **For more information:**

#### **Investor contact**

Deanne Curry

GRACosway

E: [investors@anteristech.com](mailto:investors@anteristech.com)

M: +61 414 388 997

#### **Media contact**

Nick Howe

GRACosway

[nhowe@gracosway.com.au](mailto:nhowe@gracosway.com.au)

M: +61 407 183 221

[www.anteristech.com](http://www.anteristech.com)

Twitter: [@AnterisTech](https://twitter.com/AnterisTech)

Facebook: [www.facebook.com/AnterisTech](https://www.facebook.com/AnterisTech)

LinkedIn: <https://www.linkedin.com/company/anteristech>